Nephrol Dial Transplant (1993) 8: 1338-1343
© 1993 European Renal Association-European Dialysis and Transplant Association
research-article
Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats
1Hyonam Kidney Laboratory Seoul, Korea 2Department of Pathology Soon Chun Hyang University Seoul, Korea
Correspondence and offprint requests to: Correspondence and offprint requests to: Dr Hi Bahl Lee, Hyonam Kidney Laboratory, Soon Chun Hyang University, 657 Hannam Dong, Yongsan Koo, Seoul 140–743, Korea.
To evaluate the effect of delayed treatment with enalapril or lovastatin on the progression of glomerulosclerosis and to examine if the combined treatment with enalapril and lovastatin show synergistic effect, a total of 31 Sprague-Dawley rats were studied for 16 weeks following 5/6 nephrectomy (NPX). Treatment was delayed until 8 weeks after NPX.
In untreated control rats (n=8), sustained systemic hypertension with increasing proteinuria, serum cholesterol, triglyceride, BUN and widespread glomerulosclerosis and mesangial expansion were observed.
Treatment with enalapril alone (R, n=8) reversed systemic hypertension, prevented a further increase in proteinuria, and significantly reduced glomerulosclerosis relative to the control group.
Treatment with lovastatin alone (L, n=7) also reduced glomerulosclerosis and serum cholesterol compared to the controls. The drug also prevented a further increase in proteinuria and systemic blood pressure although the difference from the control rats did not reach statistical significance.
Treatment with both enalapril and lovastatin (RL, n=8) almost completely prevented glomerulosclerosis and significantly reduced mesangial expansion, systemic blood pressure, serum cholesterol, and proteinuria compared to controls. Only the combined treatment stabilized BUN and reduced mesangial expansion compared to control R, or L groups.
Conclusion. Delayed treatment with enalapril or lovastatin is effective in preventing the progression of glomerulosclerosis, and combined treatment appears to show synergistic effect in 5/6 nephrectomized rat model.
Keywords: delayed treatment; enalapril; glomerulosclerosis; lovastatin; 5/6 nephrectomy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Kramer, S. Kron, Y. Wang-Rosenke, T. Loof, D. Khadzhynov, S. Morgera, H. Kawachi, F. Shimizu, S. Martini, H.-H. Neumayer, et al. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis Am J Physiol Renal Physiol, April 1, 2008; 294(4): F801 - F811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gianella, E. Nobili, M. Abbate, C. Zoja, P. Gelosa, L. Mussoni, S. Bellosta, M. Canavesi, D. Rottoli, U. Guerrini, et al. Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats Am. J. Pathol., April 1, 2007; 170(4): 1165 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Li, C. W. Yang, J. H. Park, S. W. Lim, B. K. Sun, J. Y. Jung, S. B. Kim, Y. S. Kim, J. Kim, and B. K. Bang Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy Am J Physiol Renal Physiol, January 1, 2004; 286(1): F46 - F57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zoja, D. Corna, D. Camozzi, D. Cattaneo, D. Rottoli, C. Batani, C. Zanchi, M. Abbate, and G. Remuzzi How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2898 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Bos, R. H. Henning, P. E. de Jong, D. de Zeeuw, and G. Navis Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition? Nephrol. Dial. Transplant., May 1, 2002; 17(5): 793 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. van Dijk, A. M. Kamper, S. van Veen, J. H. M. Souverijn, and G. J. Blauw Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant., November 1, 2001; 16(11): 2152 - 2157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. IL KIM, D. C. HAN, and H. B. LEE Lovastatin Inhibits Transforming Growth Factor-{beta}1 Expression in Diabetic Rat Glomeruli and Cultured Rat Mesangial Cells J. Am. Soc. Nephrol., January 1, 2000; 11(1): 80 - 87. [Abstract] [Full Text]
|
|
|
|
|
|
D. W. Johnson, H. J. Saunders, M. J. Field, and C. A. Pollock In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity Am J Physiol Renal Physiol, March 1, 1999; 276(3): F467 - F475. [Abstract] [Full Text] [PDF]
|
|